Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 480 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Graft-vs.-Host Disease Clear all
Completed Phase 1Phase 2 Interventional

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

NCT00021749
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL
Interventions
Oblimerson sodium, G3139
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
New Hyde Park, New York • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2009 · Synced Jun 10, 2026, 4:03 PM EDT
Recruiting Not applicable Interventional

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

NCT06464926
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Enterra Therapy System
Device
Lead sponsor
Enterra Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)

NCT06638879
View directory record Official record
Conditions
Chronic Graft Versus Host Disease Oral
Interventions
Tacrolimus
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 40 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 4:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Wound Healing Endpoint and Recurrence

NCT02577120
View directory record Official record
Conditions
Chronic Wound, Burn Wound, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, Chronic, Wound
Interventions
Epiceram Skin Barrier Function, Vaseline Petroleum Jelly
Device · Biological
Lead sponsor
Sashwati Roy
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

NCT01680965
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ofatumumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Tampa, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 10, 2026, 4:03 PM EDT
Active, not recruiting Not applicable Interventional

HFIT Versus TENS Study for Chronic Low Back and Knee Pain

NCT05821530
View directory record Official record
Conditions
Chronic Pain, Knee Pain Chronic, Back Pain, Low
Interventions
HFIT, TENS, Control
Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

NCT00103701
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic-phase, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

NCT01390402
View directory record Official record
Conditions
Leukemia, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, NK cell infusion:, Interleukin-2, Anti-Thymocyte Globulin, Allogeneic related Stem Cell Transplant, Tacrolimus, Methotrexate, G-CSF
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jun 10, 2026, 4:03 PM EDT
Recruiting Not applicable Interventional

Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation

NCT07199361
View directory record Official record
Conditions
Post-Surgical Pain, Chronic, Post-traumatic Pain, Chronic
Interventions
Peripheral Transcutaneous Magnetic Stimulation from MagVenture
Device
Lead sponsor
Florida International University
Other
Eligibility
19 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 10, 2026, 4:03 PM EDT
Recruiting Phase 2 Interventional

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Axatilimab, Biospecimen Collection, Questionnaire Administration, Skin Biopsy, Skin Measurement
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Improving Hand Recovery With Neuromodulation in Tetraplegia

NCT03954496
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Unspecified, Incomplete, Chronic
Interventions
transcranial direct current stimulation, Intensive upper extremity motor training
Device · Behavioral
Lead sponsor
Sara Shahid Salles
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jun 10, 2026, 4:03 PM EDT
Withdrawn Phase 2 Interventional

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

NCT05509582
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jun 10, 2026, 4:03 PM EDT
Completed No phase listed Observational

Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study

NCT01050959
View directory record Official record
Conditions
Chronic, Medically Refractory Headache
Interventions
bion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Phoenix, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Jun 10, 2026, 4:03 PM EDT
Not listed Phase 2 Interventional

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

NCT01158105
View directory record Official record
Conditions
Chronic Graft-versus-host Disease
Interventions
Bortezomib
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Study of Asthma and Nasal Steroids

NCT01118312
View directory record Official record
Conditions
Asthma, Rhinitis, Sinusitis
Interventions
Mometasone Furoate monohydrate, Placebo
Drug · Other
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
6 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2015 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

NCT00386334
View directory record Official record
Conditions
Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
82
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

NCT00949975
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
AZD9668, AZD9668 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Fullerton, California • Valparaiso, Indiana • Council Bluffs, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Jun 10, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00290628
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, filgrastim, melphalan, methylprednisolone, mycophenolate mofetil, radiation therapy, umbilical cord blood transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

NCT00144677
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
sirolimus, tacrolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Jun 10, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
Extracorporeal Photopheresis (ECP), Methoxsalen
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
cyclosporine, hydroxychloroquine, prednisone, tacrolimus
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jun 10, 2026, 4:03 PM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

NCT03018223
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
Drug · Radiation · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jun 10, 2026, 4:03 PM EDT